Equities
Health CareMedical Equipment and Services
  • Price (USD)18.95
  • Today's Change0.26 / 1.39%
  • Shares traded753.13k
  • 1 Year change-41.89%
  • Beta1.6863
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

  • Revenue in USD (TTM)1.01bn
  • Net income in USD-203.37m
  • Incorporated2008
  • Employees2.65k
  • Location
    Tandem Diabetes Care Inc12400 High Bluff DriveSAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 366-6900
  • Fax+1 (302) 636-5454
  • Websitehttps://www.tandemdiabetes.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inmode Ltd370.50m93.83m906.03m660.009.911.339.582.451.441.445.6710.780.47741.199.28561,356.1012.0924.2113.3026.8278.5482.3625.3338.648.83--0.000.00-6.1612.44-48.244.5715.99--
Castle Biosciences Inc343.53m-12.24m967.60m761.00--2.0731.702.82-0.4533-0.453311.6716.020.63779.056.89451,419.20-2.27-6.95-2.50-7.5279.9480.76-3.56-17.496.31--0.0218--51.0944.97131.7543.5797.74--
BioLife Solutions Inc88.83m-13.99m1.07bn159.00--3.01--12.05-0.2922-0.0611.877.370.22960.88756.18558,698.10-3.62-1.92-3.92-2.1070.0252.54-15.75-9.063.64--0.0207--8.4424.6238.27--19.15--
Novocure Ltd642.27m-177.65m1.23bn1.49k--3.61--1.92-1.61-1.615.813.050.49734.018.43431,632.40-13.75-9.61-33.14-11.8475.5777.57-27.66-19.321.50--0.6887--18.8211.4918.55--32.52--
Enovis Corp2.23bn-1.37bn1.25bn7.37k--0.6161--0.5575-24.20-24.2039.3535.330.44741.565.37303,144.60-27.38-3.14-30.81-3.5657.1952.01-61.19-9.771.160.04950.4018--23.46-8.73-1,423.10--7.58--
Iradimed Corp83.81m22.48m1.27bn160.0057.0613.4275.4715.151.751.756.527.440.8094------21.7118.0623.8620.2176.7576.8526.8225.51--------14.4321.4516.88108.61----
Tandem Diabetes Care Inc1.01bn-203.37m1.28bn2.65k--9.66--1.28-3.05-3.0515.081.961.103.258.64380,000.40-22.20-10.11-30.80-12.3353.2351.67-20.20-11.711.90-9.880.7028--25.7421.0156.86--27.42--
Conmed Corp1.37bn47.06m1.29bn3.90k27.59--10.670.94161.521.5244.24------------------54.0855.563.423.78--3.24----5.189.77-64.4737.66---5.59
Adapthealth Corp3.26bn75.81m1.38bn10.50k18.370.85442.900.42430.55530.555323.9011.940.735417.208.33310,020.301.96-2.812.28-3.1725.3219.632.67-4.190.85842.300.5253--1.9043.84112.19--70.36--
Procept Biorobotics Corp299.91m-84.58m1.55bn756.00--4.08--5.18-1.54-1.545.456.810.67721.813.91396,702.40-19.10-26.94-21.74-29.8164.5554.37-28.20-83.147.20--0.1194--64.84105.2113.68---10.34--
Pulse Biosciences Inc86.00k-74.73m1.56bn75.00--16.82--18,131.77-1.14-1.140.00131.370.0009----1,146.67-74.06-83.75-80.63-94.40-224.42---86,898.84-12,644.5210.01--0.00-------26.95---27.12--
Kestra Medical Technologies Ltd74.26m-138.79m1.57bn330.00--8.44--21.15-2.76-2.761.473.190.4034--9.40225,027.30-71.43-122.23-92.37-192.3546.40---177.06-342.51---116.720.2033--115.05---25.08--150.61--
Quidelortho Corp2.73bn-1.13bn1.60bn6.60k--0.8341--0.5867-16.66-16.6640.2728.270.44782.627.46---18.56-6.45-22.13-7.3946.6753.89-41.45-14.400.90020.67570.5798---1.8910.4444.84------
AtriCure Inc518.31m-28.77m1.62bn1.30k--3.41--3.13-0.608-0.60810.909.590.8291.688.79398,696.20-4.60-3.84-5.24-4.2574.8774.53-5.55-7.132.85-17.960.1252--16.5515.05-46.85--14.00--
Omnicell Inc1.18bn2.05m1.64bn3.60k844.321.3320.011.380.04320.043225.7027.450.57867.195.01--0.10020.73310.13570.976742.4944.800.17321.321.22--0.1198--6.535.84-83.62-42.341.93--
Data as of Feb 13 2026. Currency figures normalised to Tandem Diabetes Care Inc's reporting currency: US Dollar USD

Institutional shareholders

57.88%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20259.81m14.51%
The Vanguard Group, Inc.as of 31 Dec 20256.78m10.03%
Sessa Capital IM LPas of 30 Sep 20255.00m7.40%
ArrowMark Colorado Holdings LLCas of 30 Sep 20253.69m5.46%
GW&K Investment Management LLCas of 31 Dec 20252.68m3.96%
SSgA Funds Management, Inc.as of 31 Dec 20252.64m3.91%
Hood River Capital Management LLCas of 30 Sep 20252.55m3.78%
Paradice Investment Management LLCas of 31 Dec 20252.08m3.08%
Jennison Associates LLCas of 31 Dec 20252.02m2.99%
Freestone Grove Partners LPas of 30 Sep 20251.87m2.77%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.